Atherosclerosis is considered to be caused by many risk factors. Epidemiological studies have shownthat the co-existence of multiple risk factors contributes to the progress in the disease more heavily than a single risk factor. A high level of LDLis a very strong risk factor for coronary heart disease (CHD), showing the high incidence of angina or myocardial infarction in familial hypercholesterolemia (FH). On the other hand, HDLis a negative risk factor for CHD.It was reported in epidemiological studies that a higher level of HDLcorrelates with a lower incidence of CHD.The mechanism for such an effect has been reported by several laboratories; the reverse cholesterol transport is enhanced by the addition of HDL, dose dependently in vitro. This result means that the accumulated cholesterol can be transported to plasma by HDL,which causes a decreased cholesterol content in cells and thus prevents foam cell formation. Therefore, it has been accepted that a higher level ofHDLis preferable for the prevention of CHD.Concerning the different functions of the two lipoproteins, LDLand HDL,it is very interesting to evaluate, the risk for CHDin patients presenting both high LDL and high HDL. These different functions from the aspect of atherogenecity or antiatherogenecity, were clinically studied in the patients with FH combined with cholesteryl ester transfer protein (CETP) deficiency. In this issue, Kamigaki et al reported a case of FH with CETP deficiency who did not show CHD(1).
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The focus of their study was to evaluate the incidence of CHDand the grade of atherosclerosis in such patients. Haraki et al (2) have reported such double heterozygote cases, in which the effect of an increased HDL-Clevel caused by partial deficiency of CETPwas insufficient to prevent CHDin FH. There are manystudies on the atherogenecity of LDLboth in basic and clinical research fields. A recent study on the Japanese-American male population demonstrated that a high level of HDLin heterozygous CETPdeficiency was a positive risk factor (3) . But the patients with a higher level of HDLshowed the lower prevalence of CHDirrespective of CETPgenotype.
The results of CETPand CHDare conflicting. These data may suggest that both the quantity and quality of HDLparticles determine antiatherogenic value. Thereverse transport activity ofHDLis reported to depend on the level, or the quality ofHDL. A very high level ofHDL-C of usually over 100 mg/dl, can be observed, in homozygous CETPdeficiency. In this case, HDL is different in size, composition, electrophoretical mobility and reverse transport activity. The HDLfraction is typically divided into two different subclasses, HDL2and HDL3. HDL3fraction consists of small particles with a low cholesterol content. HDL3 maturates to form HDL2by trapping cellular cholesterol. Furthermore, the cholesterol ester in HDLis transported to the LDL or VLDLfraction by CETPin the plasma. The increased HDL observed in CETPdeficiency is similar to HDL2in size and composition. Probucol decreases the HDL-Clevel in plasma through an increase in CETPactivity, however the HDLfraction still possesses a high level of the reverse transport activity. Therefore wecannot determine the function of the HDLlevel only by its quantity. Probucol is known to activate CETPand to reduce the plasma HDLcontent. On the other hand, probucol can dramatically reduce tendon xanthoma. These data indicate that the quality of HDLeither, functional active or inactive, is very important. Furthermore, clinical studies, such as the Japan-Honolulu study (3) or the Omagari study (4) have shown that high level of HDLwith heterozygous CETPdeficiency is not antiatherogenic. In FH with a high level ofHDL, the CHDincidence is lower than with a low level of HDL(5). Therefore, the function of HDL is different between CETP deficiency and the other disease causing high level of HDL.These data suggest that treatment to increase the plasma HDLlevel should be applied on selected cases. It is very important to increase the amount of HDLpossessing a high level of reverse transport activity.
Furthermore, HDLhas other functions, such as ameliorating endothelial dysfunction, attenuating lipid peroxidation and preventing coagulation. The correlation between these functions of HDLand the quality of HDLshould be examined. The evaluation of not only quantity but also the quality of HDLis very important; in the future we should observe the quality carefully and understand its significance.
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